MétaCan
Menu
Back to cohort
Record W2153852557 · doi:10.1016/j.bbmt.2005.11.336

Second solid cancers after allogeneic stem cell transplantation: The vancouver experience

2006· article· en· W2153852557 on OpenAlexaffabout
George Gallagher, Donna E. Hogge, Thomas J. Nevill, S.H. Nantel, Michael J. Barnett, John D. Shepherd, Heather J. Sutherland, Cynthia L. Toze, Clayton A. Smith, Julye C. Lavoie, Kevin Song, Donna L. Forrest

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2006
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsVancouver General Hospital
Fundersnot available
KeywordsMedicineTransplantationStem cellSurgeryHematopoietic stem cell transplantationInternal medicineRenal cell carcinomaIncidence (geometry)Gastroenterology

Abstract

fetched live from OpenAlex

The development of second solid cancers in recipients of hematopoietic stem cell transplants (SCT) represents a serious complication among long term survivors. To assess the incidence and associated risk factors for second solid cancers following allogeneic SCT, we performed a retrospective analysis of 926 consecutive patients (pts) who underwent an allogeneic SCT between January 1985 and December 2003. Primary diagnoses were AML (235), ALL (103), CML (216), lymphoproliferative disorders (150), MDS (96), MM (80), or other (46). Median age at SCT was 39 years (range 12–65) and median time from diagnosis to SCT was 5.1 months (range 0.2–345). Six hundred forty pts had a sibling donor and 286 had an unrelated donor. Stem cell source was bone marrow (810), peripheral blood (109), or both (7). Conditioning regimens were: TBI-based (488), BuCy ± other (414), other (24). The graft was T cell depleted in 43 pts. With a median follow-up of 22.2 months post SCT (range 0.07–230.5) for all 926 pts and 84.2 months (range 8.4–230.5) for surviving pts, 30 solid malignancies have occurred in 28 pts at a median of 81.4 months post SCT (range 1.4–207.5). These second tumors involved skin (8 basal cell carcinoma, 4 invasive squamous cell carcinoma), lung (5), oral cavity (4), colon (2), bladder (2) breast (1), kidney (1), parotid gland (1), vulva-in situ (1), and primary unknown (1). Of the 28 pts, 6 died from the second cancer at a median of 6.1 months (range 0.9–36) following the diagnosis. The 10-year cumulative incidence of all second solid cancers was 3.1% (95% CI 2–5%). Compared to age and gender adjusted cancer rates in the general population of BC, the relative risk (RR) of developing a second solid cancer after allografting excluding nonmelanoma skin cancer was 1.85 (95% CI 1.04–3.06), P = .019. In multivariate analysis, significant risk factors were recipient age at SCT > 40 years (RR 4.8), P= .01 and donor gender [female donor/male recipient (RR 5.4), female donor/female recipient (RR 2.3)] P= .002. We conclude that allogeneic SCT recipients are at an increased risk of developing a second solid cancer compared to the general population, particularly if the recipient is >40 years old at the time of allografting. It is also apparent that male recipients of a female graft have a higher risk of second solid cancers. Longer follow-up is needed to more fully assess the incidence and risk factors for second solid tumors post-transplant due to their long latency period.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.045
Threshold uncertainty score0.089

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.232
Teacher spread0.224 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2006
Admission routes2
Has abstractyes

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207